Glypharma Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Glypharma General Information

Description

Developer of novel clinical therapies designed for short bowel syndrome and other rare gastrointestinal diseases. The company's therapies include a novel proprietary Glucagon-Like Peptide-2 (GLP-2) analogue, enabling patients to get hematological malignancies for myelotoxic therapies.

Contact Information

Website
www.glypharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1188 Union
  • Suite 504
  • Montreal, Quebec H3B 0E5
  • Canada
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Therachon
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1188 Union
  • Suite 504
  • Montreal, Quebec H3B 0E5
  • Canada

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glypharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 09-Oct-2018 Completed Pre-Clinical Trials
1. Early Stage VC 05-Oct-2012 Completed Pre-Clinical Trials
To view Glypharma’s complete valuation and funding history, request access »

Glypharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel clinical therapies designed for short bowel syndrome and other rare gastrointestinal diseases. The co
Biotechnology
Montreal, Canada
3 As of 2016

Houston, TX
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glypharma Competitors (72)

One of Glypharma’s 72 competitors is Marker Therapeutics, a Formerly VC-backed company based in Houston, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marker Therapeutics Formerly VC-backed Houston, TX
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Amgen Formerly PE-Backed Thousand Oaks, CA
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
Affini-T Venture Capital-Backed Watertown, MA
You’re viewing 5 of 72 competitors. Get the full list »

Glypharma Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Glypharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220233645-A1 Compositions and methods for the treatment of graft versus host disease Inactive 28-Jan-2021
US-20240123036-A1 Compositions and methods for the treatment of graft versus host disease Pending 28-Jan-2021
US-20240285730-A1 Compositions and methods for the treatment of graft versus host disease Pending 28-Jan-2021 A61K38/26

Glypharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glypharma Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
CTI Life Sciences Fund Venture Capital Minority
Ferring Pharmaceuticals PE-Backed Company Minority
Fonds de solidarite FTQ PE/Buyout Minority
To view Glypharma’s complete investors history, request access »

Ready to get started?

Request a free trial

Glypharma FAQs

  • When was Glypharma founded?

    Glypharma was founded in 2012.

  • Where is Glypharma headquartered?

    Glypharma is headquartered in Montreal, Canada.

  • What is the size of Glypharma?

    Glypharma has 3 total employees.

  • What industry is Glypharma in?

    Glypharma’s primary industry is Biotechnology.

  • Is Glypharma a private or public company?

    Glypharma is a Private company.

  • What is Glypharma’s current revenue?

    The current revenue for Glypharma is .

  • How much funding has Glypharma raised over time?

    Glypharma has raised $12M.

  • Who are Glypharma’s investors?

    CTI Life Sciences Fund, Ferring Pharmaceuticals, and Fonds de solidarite FTQ have invested in Glypharma.

  • Who are Glypharma’s competitors?

    Marker Therapeutics, Intellia Therapeutics, Amgen, Vertex Pharmaceuticals, and Affini-T are some of the 72 competitors of Glypharma.

  • When was Glypharma acquired?

    Glypharma was acquired on 09-Oct-2018.

  • Who acquired Glypharma?

    Glypharma was acquired by Therachon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »